Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.

Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M, Lun X, McFadden G, Forsyth P, Yang Y, Quan Z.

Mol Cancer. 2014 Apr 13;13:82. doi: 10.1186/1476-4598-13-82.

2.

Targeting gallbladder carcinoma: bone marrow-derived stem cells as therapeutic delivery vehicles of myxoma virus.

Weng M, Zhang M, Qin Y, Gong W, Tang Z, Quan Z, Wu K.

Chin Med J (Engl). 2014;127(12):2350-6.

PMID:
24931255
3.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

4.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2007 Sep 15;67(18):8818-27.

5.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510. Epub 2010 Jan 12.

6.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

7.

Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.

Madlambayan GJ, Bartee E, Kim M, Rahman MM, Meacham A, Scott EW, McFadden G, Cogle CR.

Leuk Res. 2012 May;36(5):619-24. doi: 10.1016/j.leukres.2012.01.020. Epub 2012 Feb 17.

8.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

9.

Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo.

Wang J, Yu Y, Yan Z, Hu Z, Li L, Li J, Jiang X, Qian Q.

Oncol Rep. 2013 Aug;30(2):833-41. doi: 10.3892/or.2013.2511. Epub 2013 May 31.

PMID:
23727990
10.

Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.

Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA.

PLoS One. 2013 Jun 6;8(6):e65801. doi: 10.1371/journal.pone.0065801. Print 2013. Erratum in: PLoS One. 2014;9(6):e101827.

11.

Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Correa RJ, Komar M, Tong JG, Sivapragasam M, Rahman MM, McFadden G, Dimattia GE, Shepherd TG.

Gynecol Oncol. 2012 May;125(2):441-50. doi: 10.1016/j.ygyno.2012.01.048. Epub 2012 Feb 1.

12.

Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA.

PLoS One. 2013 Jun 10;8(6):e66825. doi: 10.1371/journal.pone.0066825. Print 2013.

13.

E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.

Fukuda K, Abei M, Ugai H, Seo E, Wakayama M, Murata T, Todoroki T, Tanaka N, Hamada H, Yokoyama KK.

Cancer Res. 2003 Aug 1;63(15):4434-40.

14.

Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Irwin CR, Favis NA, Agopsowicz KC, Hitt MM, Evans DH.

PLoS One. 2013 Dec 31;8(12):e84134. doi: 10.1371/journal.pone.0084134. eCollection 2013.

15.

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G.

J Virol. 2007 Feb;81(3):1251-60. Epub 2006 Nov 15.

16.

E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.

Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, Murata T, Endo S, Hamada H, Hyodo I, Yokoyama KK.

Cancer Gene Ther. 2009 Feb;16(2):126-36. doi: 10.1038/cgt.2008.67. Epub 2008 Sep 26.

PMID:
18818710
17.

Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

Wennier ST, Liu J, Li S, Rahman MM, Mona M, McFadden G.

Mol Ther. 2012 Apr;20(4):759-68. doi: 10.1038/mt.2011.293. Epub 2012 Jan 10.

18.

Oncolytic myxoma virus: the path to clinic.

Chan WM, Rahman MM, McFadden G.

Vaccine. 2013 Sep 6;31(39):4252-8. doi: 10.1016/j.vaccine.2013.05.056. Epub 2013 May 29. Review.

19.

Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.

Zhang JT, Sun W, Zhang WZ, Ge CY, Liu ZY, Zhao ZM, Lu XS, Fan YZ.

BMC Cancer. 2014 Mar 15;14:193. doi: 10.1186/1471-2407-14-193.

20.

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Forsyth PA.

Cancer Res. 2005 Nov 1;65(21):9982-9990. doi: 10.1158/0008-5472.CAN-05-1201.

Supplemental Content

Support Center